Tvardi Therapeutics Inc. (NASDAQ:TVRD) stock is falling on Monday with a session volume of 5.56 million versus the average volume of 42.08 thousand, as per data from Benzinga Pro.Tvardi Therapeutics provided an update on preliminary data from the Phase 2 REVERT trial of TTI-101 alone or in addition to nintedanib (OFEV) in patients with idiopathic pulmonary fibrosis (IPF).After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC) (related to ...